GLP-1 receptor agonists are among the best-known examples of peptide-based metabolic medicines. GLP-1 stands for
glucagon-like peptide-1, a hormone involved in appetite, insulin secretion, gastric emptying, and glucose regulation.
Drugs such as semaglutide and tirzepatide are engineered to act on incretin pathways for specific medical indications.
The key point is that GLP-1 medications are not generic “wellness peptides.” They are prescription drugs with defined
indications, clinical trial data, contraindications, warnings, and dosing protocols. That makes them an important example
of how peptide science can become mainstream medicine when it is supported by rigorous evidence and regulatory
review.
How GLP-1-Based Medications Work
Semaglutide is a GLP-1 receptor agonist, meaning it activates the GLP-1 receptor. Tirzepatide is a dual GIP and GLP-1
receptor agonist, meaning it acts on both glucose-dependent insulinotropic polypeptide and GLP-1 pathways. The FDA
describes tirzepatide as activating receptors for GLP-1 and GIP to reduce appetite and food intake when used for chronic
weight management with diet and physical activity (FDA Zepbound approval announcement (https://www.fda.gov/newsevents/press-announcements/fda-approves-new-medication-chronic-weight-management)).
For weight management, these medications are approved as adjuncts to reduced-calorie diet and increased physical
activity, not as standalone substitutes for lifestyle or medical care. The FDA-approved Wegovy label lists semaglutide as
a GLP-1 receptor agonist indicated to reduce excess body weight and maintain long-term weight reduction in adults and
certain pediatric patients with obesity, and in adults with overweight plus at least one weight-related comorbid condition
(FDA Wegovy prescribing information (https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215256s024lbl.pdf)).
What Clinical Trials Showed for Semaglutide
In the STEP 1 trial, adults with overweight or obesity without diabetes received once-weekly semaglutide 2.4 mg or
placebo for 68 weeks along with lifestyle intervention. The trial reported an average body-weight change of -14.9% with
semaglutide compared with -2.4% with placebo, and 50.5% of participants in the semaglutide group achieved at least
15% weight loss compared with 4.9% in the placebo group (STEP 1 trial abstract
(https://academic.oup.com/jes/article/5/Supplement_1/A10/6240488)).
Semaglutide’s effects also raise an important long-term point: continuing therapy appears to matter for maintenance. In
STEP 4, participants who continued semaglutide after a 20-week run-in lost additional weight, while those switched to
placebo regained weight, suggesting that ongoing treatment may be needed for sustained benefit in many patients
(JAMA STEP 4 trial (https://jamanetwork.com/journals/jama/fullarticle/2777886)).
What Clinical Trials Showed for Tirzepatide
In the SURMOUNT-1 trial, adults with obesity or overweight and at least one weight-related complication, excluding
diabetes, received tirzepatide or placebo for 72 weeks. Mean weight change was -15.0% with 5 mg tirzepatide, -19.5%
with 10 mg, -20.9% with 15 mg, and -3.1% with placebo (NEJM SURMOUNT-1 trial
(http://www.nejm.org/doi/10.1056/NEJMoa2206038)).
The same trial reported that 50% of participants on 10 mg tirzepatide and 57% on 15 mg tirzepatide achieved at least
20% weight reduction, compared with 3% of placebo participants. The most common adverse events were
gastrointestinal and were generally mild to moderate, but discontinuation due to adverse events occurred more often with
tirzepatide than placebo (NEJM SURMOUNT-1 trial (http://www.nejm.org/doi/10.1056/NEJMoa2206038)).
The FDA approved Zepbound, the tirzepatide product for chronic weight management, in adults with obesity or
overweight with at least one weight-related condition, in addition to reduced-calorie diet and increased physical activity
(FDA Zepbound approval announcement (https://www.fda.gov/news-events/press-announcements/fda-approves-newmedication-chronic-weight-management)).
Safety and Medical Supervision Matter
GLP-1 and GIP/GLP-1 medications can produce meaningful metabolic effects, but they also require clinical screening
and monitoring. The FDA’s Zepbound approval announcement lists warnings for pancreatitis, gallbladder problems,
hypoglycemia, acute kidney injury, diabetic retinopathy in patients with type 2 diabetes, and suicidal behavior or thinking
(FDA Zepbound approval announcement (https://www.fda.gov/news-events/press-announcements/fda-approves-newmedication-chronic-weight-management)).
The FDA-approved Zepbound label also states that coadministration with other tirzepatide-containing products or any
GLP-1 receptor agonist is not recommended, and it describes its indication as an adjunct to diet and physical activity for
chronic weight management in defined adult populations (FDA Zepbound prescribing information
(https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217806s003lbl.pdf)).
Drug interactions and special populations also matter. A 2025 review of approved GLP-1 receptor agonists and
tirzepatide notes that clinically significant drug-metabolizing enzyme and transporter interactions have not generally been
reported, but delayed gastric emptying can affect some medications, including reported exposure changes with oral
contraceptives after tirzepatide and levothyroxine after oral semaglutide (Drug Design, Development and Therapy review
(https://www.dovepress.com/a-comprehensive-review-on-the-pharmacokinetics-and-drugdrug-interactio-peer-reviewedfulltext-article-DDDT)).
Why GLP-1s Are Different From GrayMarket Peptides
GLP-1 drugs are often discussed in the same online spaces as unapproved “research peptides,” but they belong in a
different evidence category. Semaglutide and tirzepatide have FDA-approved products, large randomized trials,
prescribing information, known safety warnings, and ongoing medical monitoring expectations. Many gray-market
peptides lack that level of clinical validation.
This distinction matters for consumers because popularity alone is not evidence. A peptide becomes medicine only when
its benefits, risks, manufacturing standards, and appropriate use have been studied and reviewed. Without that process,
marketing can move much faster than science.
The Bottom Line
GLP-1 and GIP/GLP-1 medications show how peptide-based drug design can produce major clinical impact when
supported by rigorous trials. The evidence for semaglutide and tirzepatide is far stronger than the evidence for many
wellness-marketed peptides, but these drugs still require medical supervision, proper patient selection, and attention to
safety warnings.
For readers, the takeaway is simple: GLP-1s are not casual wellness tools. They are prescription metabolic therapies that
should be evaluated with a qualified clinician.
